Diabetes Drugs: Assessing Gastric Neoplasm Risk in a Comprehensive Meta-Analysis
Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors: Network Meta-Analysis of Randomized Trials.
Background
Type 2 Diabetes is a chronic condition managed by various medications, including DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. These drug classes are highly effective for glycemic control and offer cardiovascular and renal benefits. However, concerns have occasionally been raised regarding potential long-term safety, particularly the comparative risk of developing gastric neoplasms (stomach tumors) across these widely prescribed antidiabetic drug classes.